University of Hasselt-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

2023

  1. Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 7, pp. 798-812

  2. Corrigendum to “Hyperkalemia in acute heart failure: Short term outcomes from the EAHFE registry” [American Journal of Emergency Medicine, 70C (2023) 1–9, (S0735675723002486), (10.1016/j.ajem.2023.05.005)]

    American Journal of Emergency Medicine

  3. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  4. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  5. Hyperkalemia in acute heart failure: Short term outcomes from the EAHFE registry

    American Journal of Emergency Medicine, Vol. 70, pp. 1-9

  6. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

    Frontiers in Immunology, Vol. 13

  2. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180

    Computer methods and programs in biomedicine

  3. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

    European Journal of Neurology, Vol. 29, Núm. 3, pp. 790-801

  4. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

    Frontiers in Immunology, Vol. 13

2021

  1. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, Vol. 208

  2. The FAST-FURO study: Effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 5, pp. 487-496

2020

  1. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 2, pp. 183-197

  2. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1298-1314

  3. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

2019

  1. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

    Frontiers in Neurology, Vol. 10

  2. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

    JAMA network open, Vol. 2, Núm. 9, pp. e1911750

2018

  1. Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: Viewpoint of the task force

    European Heart Journal

  2. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

    Therapeutic Advances in Neurological Disorders, Vol. 11